Perrigo Research & Development 424B5 Prospectus supplement for primary offering

0001585364333-282001S-3424B5EX-FILING FEESfalsefalsetruetrue11 0001585364 2024-09-13 2024-09-13 0001585364 1 2024-09-13 2024-09-13 0001585364 3 2024-09-13 2024-09-13 0001585364 2 2024-09-13 2024-09-13 iso4217:USD xbrli:pure xbrli:shares

Exhibit 107.1

Calculation of Filing Fee Table

424(b)(5)

(Form Type)

Issuer:

Perrigo Company plc

Perrigo Finance Unlimited Company

Guarantors:

Athena Neurosciences, LLC

Chefaro Ireland Designated Activity Company

Elan Pharmaceuticals, LLC

Galpharm Healthcare Limited

Galpharm International Limited

Gr8ness, LLC

L. Perrigo Company

Medgenix Benelux NV

OCE-BIO

BV

Perrigo Belgium NV

Perrigo Capital NV

Omega Pharma Innovation & Development NV

Omega Pharma International NV

Omega Pharma Limited

Omega Pharma Trading NV

Omega Teknika Designated Activity Company

PBM Canada Holdings, LLC

PBM Nutritionals, LLC

PBM Products, LLC

Perrigo Americas Holdings, Inc.

Perrigo Company

Perrigo Corporation Designated Activity Company

Perrigo Diabetes Care, LLC

Perrigo Direct, Inc.

Perrigo Europe Invest NV

Perrigo Finance (US) LLC

Perrigo Florida, Inc.

Perrigo Holding NV

Perrigo Holdings Unlimited Company

Perrigo International Finance Designated Activity Company

Perrigo International Holdings II, Inc.

Perrigo International Holdings, LLC

Perrigo International, Inc.

Perrigo Investments, LLC

Perrigo Ireland 1 Designated Activity Company

Perrigo Ireland 10 Unlimited Company

Perrigo Supply Chain International Designated Activity Company

Perrigo Ireland 13 Designated Activity Company

Perrigo Ireland 2 Designated Activity Company

Perrigo Ireland 4 Unlimited Company

Perrigo Ireland 5 Unlimited Company

Perrigo Ireland 6 Unlimited Company

Perrigo Ireland 9 Unlimited Company

Perrigo Management Company

Perrigo Mexico Investment Holdings, LLC

Perrigo New York, Inc.

Perrigo Pharma International Designated Activity Company

Perrigo Pharma Limited

Perrigo Research & Development Company

Perrigo Sales Corporation

Perrigo UK Acquisition Limited

PMI Branded Pharmaceuticals, Inc.

Ranir Global Holdings, LLC

Ranir (Holdings) Limited

Ranir, LLC

Wrafton Laboratories Limited

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

	Security  Type	Security Class Title	Fee Calculation or Carry Forward Rule	Amount Registered	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee (2)	Carry Forward Form Type	Carry Forward File Number	Carry Forward Initial effective date	Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward
Newly Registered Securities
Fees to Be Paid	Debt	6.125% Notes due 2032	Rule  457(r) (1)	$715,000,000	100 %	$715,000,000	0.00014760	$105,534
	Debt	5.375% Notes due 2032	Rule  457(r) (1)	$387,940,000 (1)	100 %	$387,940,000	0.00014760	$57,260
Fees Previously Paid	—	—	—	—	—	—		—
Carry Forward Securities
Carry Forward Securities	—	—	—	—	—	—			—	—	—	—
		Total Offering Amounts				$1,102,940,000		$162,794
		Total Fees Previously Paid						$0
		Total Fee Offsets						$0
		Net Fee Due						$162,794

(1) The U.S. dollar equivalent of the amount registered has been calculated using the exchange rate for September 6, 2024 of U.S. $1.1084=EUR 1, as published by Bloomberg L.P.

(2) The prospectus supplement to which this Exhibit is attached is a final prospectus for the related offerings. The maximum aggregate offering price of those offerings is $1,102,940,000.